News & Analysis on Clinical Trial Services & Contract Research And Development
By Melissa Fassbender
- Last updated on
The clinical trial laboratory services organization has named Dr. Bob Bailer as head of the vaccines business unit.
In this role, Bailer will lead lab services to support vaccine immunogenicity and efficacy studies, viral and bacterial neutralization assays across multiple platforms, custom PCR development as well as immunoassay development in ELISA and Luminex platforms.
Bailer joins the company from the National Institute of Health (NIH) where he was the director of the vaccine immunogenicity testing program. Before the NIH, Bailer held roles across pharma and US government agencies.
“I am excited to be joining the Q2 Solutions vaccine group,” said Bailer. “It is a privilege to be joining this renowned group of scientists with decades of experience of support for vaccine clinal trial testing.”
Bailer told us he will be focusing his efforts on building the strategy and tactics to enable the team to “expand upon the strong foundation while pursuing investment and innovation.”
“I see two areas of focus in the coming months,” he explained. “First, to enhance the customer experience we will be closely evaluating our business processes and systems with a keen eye for how we can better meet our customer’s evolving needs.
“Additionally, we will continue investments in talent and resources to drive a scientific leadership position by expanding our testing portfolio to meet the growing and changing needs of the vaccine clinal testing marketplace.”